In acute myeloid leukemia (AML), GPER1 expression is significantly down-regulated in tumor blasts, and its pharmacological activation via G-1 agonist impairs in vitro and in vivo leukemogenesis, improving CD8+ T cell functions and enhancing venetoclax activity [19]; similarly, the cytotoxic activity of G-1 was reported against T-cell lymphoblastic leukemia [20]. Here, GPER1 is linked to acute myeloid leukemia.